PD-L1 assay comparability study published Staburo supported the evaluation of the first multicentric analytical comparability study of PD-L1 expression in urothelial bladder cancer using four clinically developed immunohistochemistry assays. Statistical analyses...

R Shiny App for Standardized Detection of Outliers in Bioassay Development The availability of reliable and sensitive assays is an important building block in the production and quality control of biological products. In the development of such assays, unusual or...

New employee @ Staburo We are very happy to welcome Dr. Yesilda Balavarca in our team. Yesilda joins Staburo with her work experience from Deutsches Krebsforschungszentrum (DKFZ) Heidelberg and her excellent education background from University of Hasselt and...

Training @ Staburo: Response Evaluation Criteria in Solid Tumors (RECIST)At Staburo, we are working on a lot of oncology projects. Dealing with data from this particular therapeutic area does not only require good statistical knowledge, but also to understand how the...

Staburo @ DAGStat Conference 2019 Several Staburo statisticians attended the DAGStat Conference 2019. The fifth conference of the Deutsche Arbeitsgemeinschaft Statistik took place in the heart of the Bavarian capital, Munich, from March 18 - 22, 2019.According to the...

Training @ Staburo: How to measure the abundance of mRNA, using Microarrays and Sequencing TechnologiesThe normal function of cells depends on accurate expression of a large number of proteins. As it is difficult to measure the number of thousands of proteins...

Staburo @ BIO-M Workshop: Start thinking with the end in mind: Using the right Data in Clinical Development and Market AccessStaburo's Managing Director Roland Stieger attended the BioM seminar with the topic “Using the right Data in Clinical Development and Market...